|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Systematic use of recurrent laryngeal nerve neuromonitoring changes the operative strategy in planned bilateral thyroidectomy 显示文摘 | Sadowski SM Soardo P Leuchter I | 2013 | Thyroid2013，23，3： | 1 |
| 2 | Biological synthesis of goldnanostructures using the extract of Trichoderma koningii 显示文摘 | Maliszewska I Sadowski Z | 2009 | ActaPhysicaPolonicaA2009，，116： | 1 |
| 3 | Synthesis of silver nanoparticles using microorganisms 显示文摘 | Sadowski Z Maliszewska I Grochowalska B | 2008 | Materials Science: Poland2008，26，2： | 1 |
| 4 | The effect of biopretreatment on the flotation recovery of magnesite tailings显示文摘 | Gawel J Maliszewska I Sadowski Z | 1997 | Minerals Engineering1997，10，8： | 1 |
| 5 | A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of fujinami sarcoma virus p130GAG-FPS显示文摘 | Sadowski I Stone J C Pawson T | 1986 | Molecular and Cellular Biology1986，6，： | 1 |
| 6 | The sequence structure relation-ship and protein function prediction显示文摘 | M I Sadowski D T Jones | 2009 | Current Opinion in Structural Biology2009，19，3： | 1 |
| 7 | The Suv39H1 methyltransferase inhibitor chaetocin causes induction of integrated HIV-1 without producing a T cell response显示文摘 | Bernhard W Barreto K Saunders A Dahabieh MS Johnson P Sadowski I | 2011 | FEBS Lett2011，585，22： | 1 |
| 8 | Agglomerate flotation of fine oxide particles 显示文摘 | SADOWSKI Z POLOWCZYK I | 2004 | International Journal of Mineral Processing2004，74，1： | 1 |
| 9 | An experimental investigation of micro- channel flow with internal pressure measurements显示文摘 | Kohl M J Abdel-Khalik S I Jeter S M Sadowski D L | 2005 | International Journal of Heat and Mass Transfer2005，48，8： | 1 |
| 10 | pGenTHREAD- ER and pDomTHREADER: new methods for improved pro- tein fold recognition and superfamily discrimination 显示文摘 | LOBLEY A SADOWSKI M I JONES D T | 2009 | Bioinformaties2009，25，14： | 1 |
| 11 | Left ventriculartrue aneurysm without coronary artery occlusion-a case study显示文摘 | Sadowski I Wierzbicki K Wojci kS | 2002 | Przegl Lek2002，59，3： | 1 |
| 12 | Signaling from endosomes:Location makes a difference显示文摘 | Sadowski L Pilecka I Miaczynska M | 2009 | Exp Cell Res2009，315，9： | 1 |
| 13 | Treatment of reverseoblique and transverse intertrochanlerie fraetures with use of anintramedullary nail of 95°serew-plate 显示文摘 | Sadowski C I ubbeke A Saudan M | 2002 | J Bone Joint Surg(Br)2002，84，： | 1 |
| 14 | Wild type GAL4binds cooperatively to the GAL1-10 UASG in vitro显示文摘 | KANG T MARTINS T SADOWSKI I | 1993 | JBiol Chem1993，268，13： | 1 |
| 15 | The effect of biopretreatment on the flotation recovery of magnesite tailings显示文摘 | Gawel J Maliszewska I Sadowski Z | 1997 | Minerals Engineering1997，10，8： | 1 |
| 16 | Three-dimensional solution for the stress concentration around a circular hole in a plate of arbitrary thickness 显示文摘 | Sadowsky M A Chicago I L L | 1949 | J Appl Mech1949，16，1： | 1 |
| 17 | Multiple signals regulate GAL transcription in yeast显示文摘 | Rohde JR Trinh J Sadowski I | 2000 | Molecular and Cellular Biology2000，20，11： | 1 |
| 18 | GAL4 is phos-phorylated as a consequence of transcriptional activation显示文摘 | SADOWSKI I NIEDBALA D WOOD K | 1991 | ProcNatl Acad Sci USA1991，88，10： | 1 |
| 19 | GAIA-VP16 is an unusually potent transcriptional activator显示文摘 | Sadowski I Ma J Triezenberg S | 1988 | Nature1988，335，6190： | 1 |
| 20 | Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation显示文摘AIM:To investigate genetic differences between Crohn's disease(CD) patients with a sustained remission vs relapsers after discontinuing infliximab while in corticosteroid-free remission.METHODS:Forty-eight CD patients received infliximab and were in full corticosteroid-free clinical remission but then discontinued infliximab for reasons other than a loss of response,were identified by review of an electronic database and charts.Infliximab-associated remission was defined as corticosteroid-free plus normalization of clinical disease activity [CD activity index(CDAI) < 150] during follow-up visits based on physician global assessments.A CD relapse(loss of infliximab-induced remission) was clinically defined as a physician visit for symptoms of disease activity(CDAI > 220) and a therapeutic intervention with CD medication(s),or a hospitalization with complications related to active CD.Genetic analyses were performed on samples from 14 patients(n = 6 who had a sustained long term remission after stopping infliximab,n = 8 who rapidly relapsed after stopping infliximab).Nucleotide-binding oligomerization domain 2(NOD2)/caspase activation recruitment domain 15(CARD15) polymorphisms(R702W,G908R and L1007fs) and the inflammatory bowel disease 5(IBD5) polymorphisms(IGR2060a1 and IGR3081a1) were analyzed in each group.RESULTS:Five single nucleotide polymorphisms of IBD5 and NOD2/CARD15 genes were successfully analyzed for all 14 subjects.There was no significant increase in frequency of the NOD2/CARD15 polymorphisms(R702W,G908R and L1007fs) and the IBD5 polymorphisms(IGR2060a1 and IGR3081a1) in either group of patients;those whose disease relapsed rapidly or those who remained in sustained long term remission following the discontinuation of infliximab.Nearly a third of patients in full clinical remission who stopped infliximab for reasons other than loss of response remained in sustained clinical remission,while two-thirds relapsed rapidly.There was a marked difference in the duration of clinical remission following discontinuance of infliximab between the two groups.The patients who lost remission did so after 1.0 years ± 0.6 years,while those still in remission were at the time of this study,8.1 years ± 2.6 years post-discontinuation of infliximab,P < 0.001.The 8 patients who had lost remission after discontinuing infliximab had a mean number of 5 infusions(range 3-7),with a mean treatment time of 7.2 mo(range 1.5 mo-15 mo).The mean duration of time from the last infusion of infliximab to the time of loss of remission was 382 d(range 20 d-701 d).The 6 patients who remained in remission after discontinuing infliximab had a mean number of 6 infusions(range 3-12),with a mean treatment duration of 12 mo(range 3.6 mo-32 mo)(P = 0.45 relative to those who lost remission).CONCLUSION:There are no IBD5 or NOD2/CARD15 mutations that predict which patients might have sustained remission and which will relapse rapidly after stopping infliximab. | Cathy Lu Alistair Waugh Robert J Bailey Raeleen Cherry Levinus A Dieleman Leah Gramlich Kata Matic Mario Millan Karen I Kroeker Daniel Sadowski Christopher W Teshima Dennis Todoruk Clarence Wong Karen Wong Richard N Fedorak | 2012 | World Journal of Gastroenterology2012，18，36： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员